Skip to main content
Home > Week in Review > Sales & Marketing

Chronological Index of : Sales and Marketing

 Current Issue
  • bioMerieux, Quest Diagnostics sales and marketing update

    bioMerieux S.A. (Euronext:BIM), Marcy lEtoile, France Quest Diagnostics Inc. (NYSE:DGX), Madison, N.J. Business: Pharmacogenetics Quest launched bioMerieuxs THxID BRAF test in the U.S. to detect BRAF V600E and V600K …

    Published on 6/30/2014
  • Medivir sales and marketing update

    Medivir AB (SSE:MVIR B), Huddinge, Sweden Business: Infectious Medivir launched Olysio simeprevir in Sweden, Finland and Denmark and said the HCV drug will be available in all Nordic countries within the next few weeks…

    Published on 6/30/2014
  • Takeda sales and marketing update

    Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Autoimmune Takeda launched Entyvio vedolizumab in the U.S. to treat moderate to severe ulcerative colitis (UC) and moderate to severe Crohns disease (…

    Published on 6/30/2014
  • Alvogen, Celltrion, Hospira sales and marketing update

    Alvogen Inc., Pinebrook, N.J. Celltrion Inc. (KOSDAQ:068270), Incheon, South Korea Hospira Inc. (NYSE:HSP), Lake Forest, Ill. Business: Biosimilars, Autoimmune Alvogen launched Inflectra infliximab, a biosimilar of …

    Published on 2/17/2014
  • Cardiome, Phoenix Pharmahandel sales and marketing update

    Cardiome Pharma Corp. (TSX:COM; NASDAQ:CRME), Vancouver, B.C. Phoenix Pharmahandel GmbH & Co. KG, Mannheim, Germany Business: Cardiovascular Cardiome's Correvio GmbH subsidiary granted Phoenix Pharmahandels Tamro AB …

    Published on 2/17/2014
  • Covis, GlaxoSmithKline sales and marketing update

    Covis Pharma S.a.r.l., Zug, Switzerland GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Business: Cardiovascular Covis launched 0.0625 and 0.1875 mg strengths of Lanoxin digoxin in the U.S. to treat mild to …

    Published on 2/17/2014
  • Foundation Medicine, AmerisourceBergen Corp. sales and marketing update

    Foundation Medicine Inc. (NASDAQ:FMI), Cambridge, Mass. AmerisourceBergen Corp. (NYSE:ABC), Valley Forge, Pa. Business: Pharmacogenetics AmerisourceBergen's Ion Solutions pharmaceuticals arm selected Foundation Medicine…

    Published on 2/17/2014
  • Icahn School of Medicine at Mount Sinai sales and marketing update

    Icahn School of Medicine at Mount Sinai, New York, N.Y. Business: Neurology The medical school launched a carrier screening test for spinal muscular atrophy (SMA). The test detects silent carriers with two copies of the…

    Published on 2/17/2014
  • Illumina, Rubicon sales and marketing update

    Illumina Inc. (NASDAQ:ILMN), San Diego, Calif. Rubicon Genomics Inc., Ann Arbor, Mich. Business: Diagnostic, Genomics Rubicon launched the PicoPlex DNA-seq kits worldwide for use with Illumina's next-generation …

    Published on 2/17/2014
  • Nuvo, Mallinckrodt sales and marketing update

    Nuvo Research Inc. (TSX:NRI), Mississauga, Ontario Mallinckrodt plc (NYSE:MNK), St. Louis, Mo. Business: Neurology Mallinckrodt launched Pennsaid 2% diclofenac in the U.S. to treat pain associated with osteoarthritis (…

    Published on 2/17/2014
  • SkyePharma, Mundipharma sales and marketing update

    SkyePharma plc (LSE:SKP), London, U.K. Mundipharma International Ltd., Cambridge, U.K. Business: Inflammation, Drug delivery SkyePharma said Mundipharma launched flutiform fluticasone/formoterol in France to treat …

    Published on 2/17/2014
  • Theravance, GlaxoSmithKline sales and marketing update

    Theravance Inc. (NASDAQ:THRX), South San Francisco, Calif. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K. Business: Pulmonary Theravance disclosed in its 2013 financial results that GlaxoSmithKline launched …

    Published on 2/17/2014
  • Ariad, Specialised Therapeutics Australia sales and marketing update

    Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), Cambridge, Mass. Specialised Therapeutics Australia Pty. Ltd., Melbourne, Australia Business: Cancer Ariad granted Specialised Therapeutics exclusive, Australian …

    Published on 2/3/2014
  • Cancer Genetics sales and marketing update

    Cancer Genetics Inc. (NASDAQ:CGIX), Rutherford, N.J. Business: Diagnostic Cancer Genetics said that U.S. healthcare preferred provider organization (PPO) Three Rivers Provider Network will cover the company's cancer …

    Published on 2/3/2014
  • Integrated BioTherapeutics, Noble Life Sciences sales and marketing update

    Integrated BioTherapeutics Inc., Gaithersburg, Md. Noble Life Sciences Inc., Gaithersburg, Md. Business: Supply/Service Noble and Integrated BioTherapeutics' IBT Bioservices research services division launched an …

    Published on 2/3/2014
  • Kyowa Hakko Kirin sales and marketing update

    Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151), Tokyo, Japan Business: Hematology Kyowa launched the 5 g NESP darbepoetin alfa injection plastic syringe in Japan to treat anemia in pediatric and adult patients with chronic …

    Published on 2/3/2014
  • Lundbeck, Takeda sales and marketing update

    H. Lundbeck A/S (CSE:LUN), Copenhagen, Denmark Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Business: Neurology Takeda and partner H. Lundbeck launched once-daily Brintellix vortioxetine in the U.S. to …

    Published on 2/3/2014
  • MDxHealth, Teva sales and marketing update

    MDxHealth S.A. (Euronext:MDXH), Liege, Belgium Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), Petah Tikva, Israel Business: Diagnostic MDxHealth granted Teva exclusive rights to commercialize PredictMDx for …

    Published on 2/3/2014
  • Aerocrine, Healthcare 21 Ltd. sales and marketing update

    Aerocrine AB (SSE:AERO), Solna, Sweden Healthcare 21 Ltd., Cork, Ireland Business: Diagnostic Aerocrine granted Healthcare 21 exclusive rights to market Niox Vero and Niox Mino in the U.K. and Ireland. Niox Mino and …

    Published on 1/27/2014
  • Alexza, Ferrer sales and marketing update

    Alexza Pharmaceuticals Inc. (NASDAQ:ALXA), Mountain View, Calif. Grupo Ferrer Internacional S.A., Barcelona, Spain Business: Neurology Ferrer launched Adasuve Staccato loxapine in Spain. The launch triggered a $1 …

    Published on 1/27/2014
  • Angelini, Helsinn sales and marketing update

    Gruppo Angelini, Rome, Italy Helsinn Healthcare S.A., Pazzallo-Lugano, Switzerland Business: Endocrine/Metabolic Helsinn granted Angelini's CSC Pharmaceuticals Handels GmbH subsidiary exclusive rights to commercialize …

    Published on 1/27/2014
  • Biocon sales and marketing update

    Biocon Ltd. (NSE:BIOCON; BSE:BIOCON), Bangalore, India Business: Biosimilars, Cancer Biocon said it will launch Canmab - its biosimilar of Herceptin trastuzumab - in India in the first week of February. The Drugs …

    Published on 1/27/2014
  • Biogen Idec sales and marketing update

    Biogen Idec Inc. (NASDAQ:BIIB), Weston, Mass. Business: Autoimmune Biogen Idec launched Fampyra fampridine in Ireland to improve walking ability in patients with multiple sclerosis (MS). Fampyra is not available for …

    Published on 1/27/2014
  • CollabRx, Cynvenio Biosystems sales and marketing update

    CollabRx Inc. (NASDAQ:CLRX), San Francisco, Calif. Cynvenio Biosystems Inc., Westlake Village, Calif. Business: Pharmacogenetics CollabRx launched its Therapy Finder for breast cancer patients who order Cynvenio's …

    Published on 1/27/2014
  • CombiMatrix, Galaxy Health Network sales and marketing update

    CombiMatrix Corp. (NASDAQ:CBMX), Irvine, Calif. Galaxy Health Network, Arlington, Texas Business: Diagnostic CombiMatrix said U.S. healthcare provider Galaxy Health Network will cover CombiMatrix's molecular diagnostic …

    Published on 1/27/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993